Retrospective observational study of salvage chemotherapy following nivolumab therapy in advanced non-small cell lung cancer
Not Applicable
- Conditions
- non-small cell lung cancer
- Registration Number
- JPRN-UMIN000032667
- Lead Sponsor
- Department of Respiratory Medicine, Sasebo City General Hospital
- Brief Summary
Both few PD-1 positive immune cells in the tumor and decreased NLR ratio during the treatment may predict the improved response to salvage chemotherapy following nivolumab for lung cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
The patients are excluded from the analysis if they had another neoplasm for the need of treatment, and if they received the preceding therapy of EGFR or ALK throsine kinase inhibitors before or after nivolumab therapy.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoint is overall response of salvage chemotherapy in association with the characteristics of tumor-infiltrating immune cells.
- Secondary Outcome Measures
Name Time Method The secondary endpoint is progression-free survival of salvage chemotherapy,